Be a Part of the Community at the Nation’s Premier Drug and Med Litigation Conference, and Stay on the Cutting Edge of Evolving Defense Strategies and Emerging Theories of Liability.

Dear Colleague,

ACI’s 19th Annual Drug and Med Litigation conference is the only event which brings together an exceptional in-house presence on the faculty, the top defense firms representing biopharmaceutical and medical device companies, experienced jurists from around the country, the FDA, and the DOJ. Designed for both networking and masters-level strategy sharing, this is the leading forum at which to learn winning life sciences products liability litigation strategies.

Our accomplished faculty and our new Drug and Med Advisory Board - a veritable “Who’s Who” of the products liability defense bar - have united to refresh this year’s agenda and will provide comprehensive updates and strategic solutions to the latest challenges.

Not surprisingly, 2014 brought several more exorbitant verdicts and creative gamesmanship by the plaintiffs’ bar: 9 billion verdict stemming from alleged defense discovery violations and spoliation in a bellwether trial…attempts to defeat CAFA removal provisions by filing just under 100 lawsuits in state court…using third parties to fund litigation…the list goes on. By attending this conference, you will get practical advice on crafting the most effective theories and defenses in mass tort litigation from the leading litigators in the field as well as from over 20 in-house counsel responsible for handling litigation on behalf of the country’s top life sciences companies. Our unparalleled faculty — including in-house representatives from Bayer, C.R. Bard, Eli Lilly and Company, GSK, Johnson & Johnson, Medtronic, Novo Nordisk, Pfizer, Purdue, St. Jude Medical,
Teva
and many more — will share the methods that have worked for them in recent battles, and provide specific advice for both defeating claims and for litigating efficiently and cost-effectively. Additionally, to give a 360 degree view of the challenges facing the industry, attendees will have the opportunity to hear from a leading panel of judges, as well as the FDA on generic preemption and the DOJ on criminal enforcement stemming from civil products liability.

Faced with ever-evolving tactics from the plaintiffs’ bar and amplified scrutiny by the public and the government, there is simply no room for error in this no-holds-barred fight.

Be part of a community of peers fighting the same litigation challenges with a goal of bringing and keeping safe and effective therapies on the market for the patients who rely on them.  Register early to ensure best pricing.  Group discounts are available.  Call 1-888-224-2480, fax your registration to 1-877-927-1563, or online.

Additionally, please join the ACI: Drug and Medical Device Litigation group on LinkedIn to ‘meet’ your peers prior to the start of the conference, and follow us on Twitter @DrugandMed for industry news and exclusive discounts.

I hope you will join us this December in New York City at the premier industry showcase for meeting the people who will shape the law in the year to come. We also hope that in addition to the substantive value of this conference that you will also enjoy all the vibrant cultural resources and networking opportunities that this event offers.

Very truly yours,


Nicole M. Cutrufello-Turner, J.D.
Legal Analyst and Senior Conference Director

P.S. When making your travel arrangements, plan on attending three new sessions designed for heightened networking and creating a candid dialogue about this litigation in a less formal session:

Pre-Conference Group Meet-Ups (INCLUDED IN YOUR REGISTRATION): Year in Review: Identifying, Analyzing, and Defending Against Emerging Theories of Drug and Device Liability and Evolving Plaintiffs’ Tactics

Pre-Conference Workshop: View from the General Counsel’s Office: Limiting Liability and Managing and Reducing Costs in Drug and Med Litigation

Post-Conference Workshop: Ethics: Inclusion and Diversity and the Products Liability Bar: Exploring the Challenges and Opportunities in Attracting and Retaining Diverse Trial Counsel